PF-00562271

Catalog No.S2672 Synonyms: PF-562271 Besylate

PF-00562271 Chemical Structure

Molecular Weight(MW): 665.66

PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.

Size Price Stock Quantity  
USD 270 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Mol Ther 2012 20(5), 972-83. PF-00562271 purchased from Selleck.

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Targets
FAK [1]
(Cell-free assay)
PYK2 [1]
(Cell-free assay)
CDK2/CyclinE [1]
(Cell-free assay)
CDK3/CyclinE [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
1.5 nM 13 nM 30 nM 47 nM 58 nM
In vitro

PF-562271 shows the selective inhibitory effects on FAK and Pyk2 tyrosine kinase activity with IC50 of 1.5 nM and 14 nM, respectively. And in cell-based assays, the IC50 of PF-562271 is shown to be 5 nM for FAK, which is more selective compared to other kinase targets. [1] In 2 dimensional (2D) cultures, PF-562271 results in a dose-dependent cell proliferation inhibition in FAK WT, FAK−/− and FAK kinase-deficient (KD) cells with IC50 of 3.3 μM, 2.08 μM and 2.01 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 cell NXnncI1zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn\TTY5pcWKrdHnvckBw\iCqdX3hckBOXi12LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzZ4IN88US=> M3XYSHNCVkeHUh?=
human SW982 cell M3[wfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPM[|BIUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6MjFOwG0> NUHZSmFKW0GQR1XS
human KM12 cell Ml25S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NETNR3BKdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM5PTV5IN88US=> MWPTRW5ITVJ?
human COLO-205 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3PMPWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz2yNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR6NkW4JO69VQ>? MV;TRW5ITVJ?
human COLO-829 cell M17Ne2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vOEK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PjF5NjFOwG0> MkCzV2FPT0WU
human MG-63 cell M{GxUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHrHWolKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45ODZ|NzFOwG0> MnOwV2FPT0WU
human IGROV-1 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1nXOWlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDFyM{ig{txO MX3TRW5ITVJ?
human NCI-H650 cell NGD5OY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2\SZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh|MUW0JO69VQ>? NIHSRnVUSU6JRWK=
human RT-112 cell NVKxc5l4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVzLNJU4UW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl6NE[g{txO NWPPTHFNW0GQR1XS
human BCPAP cell NGi0XXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVXieHJYUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODF{OEig{txO NV\rdpJFW0GQR1XS
ALL-PO cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3PU[mlvcGmkaYTpc44hd2ZiaIXtZY4hSUyOLWDPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xOTV6NDFOwG0> MoPmV2FPT0WU
human KYSE-270 cell NYXFZW1rT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHpS2JMUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMES3NVQh|ryP NGHVflNUSU6JRWK=
human 8305C cell NVfjUFh5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVm4fllCUW6qaXLpeIlwdiCxZjDoeY1idiB6M{C1R{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODl7MESg{txO NWe3[3U1W0GQR1XS
NCI-H810 cell NHS1PXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmPiTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTB5N{[g{txO MWnTRW5ITVJ?
human CAL-33 cell NGTHPI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVI6OzhizszN NU\JZoZTW0GQR1XS
human AN3-CA cell NHHhWHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml[1TY5pcWKrdHnvckBw\iCqdX3hckBCVjNvQ1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIyQDZ5IN88US=> MVvTRW5ITVJ?
human NKM-1 cell MnLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yO|UxPiEQvF2= M{Hmb3NCVkeHUh?=
human BPH-1 cell MkG3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXL3RoJRUW6qaXLpeIlwdiCxZjDoeY1idiCEUFitNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjh5Nk[g{txO M3\peXNCVkeHUh?=
human MES-SA cell M{nxW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVXJcohq[mm2aX;uJI9nKGi3bXHuJG1GWy2VQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|A3QDJizszN NEW0WoFUSU6JRWK=
human CAL-62 cell NHi1WGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUCzRmx[UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNzOUC5JO69VQ>? MmXmV2FPT0WU
human KYSE-150 cell NUH6OXJQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlT3TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzV{M{[g{txO MlXEV2FPT0WU
human SK-UT-1 cell M2XwcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoC3TY5pcWKrdHnvckBw\iCqdX3hckBUUy2XVD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PDZ2NzFOwG0> MlnOV2FPT0WU
human HUTU-80 cell NFrW[3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTjO2NKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjR2OEi2JO69VQ>? NF;keVJUSU6JRWK=
human SIG-M5 cell NWLSZ2F[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkGyTY5pcWKrdHnvckBw\iCqdX3hckBUUUdvTUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ5PDh5IN88US=> M{nWR3NCVkeHUh?=
human AGS cell NX\Mbmk{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1zyRWlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61NlEzPCEQvF2= NHzpRolUSU6JRWK=
human ST486 cell Mlq3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3RfFZVUW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTN{N{ig{txO MWrTRW5ITVJ?
human HSC-2 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmfTTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVM6PSEQvF2= MX7TRW5ITVJ?
human BC-1 cell NEjzfpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHvod|BKdmirYnn0bY9vKG:oIHj1cYFvKEKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyPjZ2IN88US=> M2jRRXNCVkeHUh?=
human CGTH-W-1 cell NGn2WIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{XoO2lvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZzNke5JO69VQ>? NInITIxUSU6JRWK=
human MZ1-PC cell Ml;aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjITY5pcWKrdHnvckBw\iCqdX3hckBOYjFvUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzOzF{IN88US=> Ml;ZV2FPT0WU
human SW1710 cell MkPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYP2WZlVUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ{NkK4JO69VQ>? MYnTRW5ITVJ?
human EW-13 cell MlrLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnnFTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlM1PjZizszN MmnFV2FPT0WU
human U251 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFPGUFdKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc1ODNzIN88US=> M1:4fXNCVkeHUh?=
human NCI-H460 cell NXvBdmkxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXoOYhiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMES4N|kh|ryP MXnTRW5ITVJ?
human DU-4475 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUPtd2doUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5zNEe1PUDPxE1? NVfFPW5zW0GQR1XS
human MFE-296 cell NWHXNphzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\I[2dKdmirYnn0bY9vKG:oIHj1cYFvKE2IRT2yPVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR5N{myJO69VQ>? NVnRWJdEW0GQR1XS
human DU-145 cell MlWxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1TabWlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41QTFzODFOwG0> NUPwPGNZW0GQR1XS
human MDA-MB-231 cell M1q5OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1:yOGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNEm1O|Ih|ryP MVvTRW5ITVJ?
human SNU-387 cell NUPVUXJET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEXYdJVKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV{OEKg{txO MmHkV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In several human s.c. xenograft models, PF-562271 exhibits dose-dependent tumor growth inhibition, and produces maximum tumor inhibition for PC-3M, BT474, BxPc3, and LoVo ranging from 78% to 94% inhibition at doses of 25 to 50 mg/kg twice daily, without weight loss, morbidity, or death. [1] PF-562271 (25 mg/kg by p.o.) leads to a significant decrease in tumor progression in both subcutaneous and bone metastasis PC3M-luc-C6 xenograft models. [3] In a Huh7.5 hepatocellular carcinoma xenograft model, combination therapy of sunitinib and PF-562271 targets angiogenesis and tumor aggressiveness, and produces more significant anti-tumor effect than single agent by blocking tumor growth and impacting the ability of the tumor to recover upon withdrawal of the therapy. [4]

Protocol

Kinase Assay:[1]
+ Expand

Recombinant kinase assay and enzyme kinetics :

Briefly, purified-activated FAK kinase domain (amino acid 410–689) is reacted with 50 μM ATP and 10 μg per well of a random peptide polymer of Glu and Tyr, p(Glu/Tyr), in kinase buffer [50 mM HEPES (pH 7.5), 125 mM NaCl, and 48 mM MgCl2] for 15 minutes. Phosphorylation of p(Glu/Tyr) is challenged with serially diluted PF-562271 at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is tested in triplicate. Phosphorylation of p(Glu/Tyr) is detected with a general antiphospho-tyrosine (PY20) antibody followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody. HRP substrate is added, and absorbance readings at 450 nm are obtained after addition of stop solution (2 M H2SO4). IC50 values are determined using the Hill-Slope Model. Broad kinase selectivity profiling is performed in house and by using the KinaseProfiler Selectivity Screening Service available through UpState Biotechnology.
Cell Research:[2]
+ Expand
  • Cell lines: Squamous cell carcinoma (SCC)
  • Concentrations: 0 to 1 μM
  • Incubation Time: 72 hours
  • Method: Cells are plated for 48 hours before addition of PF-562271. After 3 days cells are fixed by addition of ice cold 25% trichloroacetic acid (TCA) solution prior to staining with Sulforhodamine B (SRB) dye solution. Plates are washed with 1% glacial acetic acid, air-dried and resuspended in 10 mM Tris buffer, pH 10.5 before reading absorbance at 540 nm. Curve fitting and generation of IC50 values is carried out using GraphPad Prism 4 software from six replicates.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: PC-3M, BT474, BxPc3, LoVo, U87MG, H125 and H460 cells are injected s.c. into the right flank of athymic female mice .
  • Formulation: PF-562271 is dissolved in 5% Gelucire.
  • Dosages: ≤100 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (21.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 665.66
Formula

C21H20F3N7O3S.C6H6O3S

CAS No. 939791-38-5
Storage powder
Synonyms PF-562271 Besylate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00666926 Completed Head and Neck Neoplasm|Prostatic Neoplasm|Pancreatic Neoplasm Verastem, Inc. December 2005 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the difference between S2890 and S2672?

  • Answer:

    S2890 is free base and S2672 is the besylate salt, S2672 has better solubility than S2890.

  • Question 2:

    We are planning both in vitro and in vivo experiments and want to know how to reconstitute the drug for these purposes?

  • Answer:

    PF-00562271 has poor solubility in DMSO and water. Its solubility in DMSO is only 0.4mg/ml. In a previous literature report (http://www.ncbi.nlm.nih.gov/pubmed/18339875), the author used 5% Gelucire to formulate the compound. You can also consider other co-solvents such as PEG400, CMC, Tween80, and Captisol.

  • Question 3:

    Can you provide with a few common vehicles for PF-00562271, S2672 for use as oral gavage?

  • Answer:

    S2672 PF-00562271 can be dissolved in 0.5% CMC Na at 30 mg/ml as a suspension. If 4% DMSO can be used in your experiment, it will help dissolving the suspension more homogeneously.

Related Antibodies

FAK Signaling Pathway Map

Related FAK Products

Tags: buy PF-00562271 | PF-00562271 supplier | purchase PF-00562271 | PF-00562271 cost | PF-00562271 manufacturer | order PF-00562271 | PF-00562271 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID